Literature DB >> 27640324

Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.

G Sanacora1, H Heimer2, D Hartman3, S J Mathew4, M Frye5, C Nemeroff6, R Robinson Beale7.   

Abstract

Entities:  

Year:  2016        PMID： 27640324      PMCID： PMC5437876          DOI： 10.1038/npp.2016.193

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

Authors:  Jaskaran B Singh; Maggie Fedgchin; Ella J Daly; Peter De Boer; Kimberly Cooper; Pilar Lim; Christine Pinter; James W Murrough; Gerard Sanacora; Richard C Shelton; Benji Kurian; Andrew Winokur; Maurizio Fava; Husseini Manji; Wayne C Drevets; Luc Van Nueten
Journal:  Am J Psychiatry       Date:  2016-04-08       Impact factor: 18.112

Review 2.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

Review 3.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

Authors:  D Jeffrey Newport; Linda L Carpenter; William M McDonald; James B Potash; Mauricio Tohen; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2015-10       Impact factor: 18.112

4.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

5.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

6.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962
  6 in total
  13 in total

1.  Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.

Authors:  Samuel T Wilkinson; Rachel B Katz; Mesut Toprak; Ryan Webler; Robert B Ostroff; Gerard Sanacora
Journal:  J Clin Psychiatry       Date:  2018-07-24       Impact factor: 4.384

Review 2.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

3.  Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Authors:  Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch
Journal:  Neuropsychopharmacology       Date:  2017-08-29       Impact factor: 7.853

Review 4.  Glutamatergic Modulators in Depression.

Authors:  Ioline D Henter; Rafael Teixeira de Sousa; Carlos A Zarate
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

5.  What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?

Authors:  Carlos A Zarate
Journal:  Am J Geriatr Psychiatry       Date:  2017-08-30       Impact factor: 4.105

6.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Authors:  Ruin Moaddel; Michelle Shardell; Mohammed Khadeer; Jacqueline Lovett; Bashkim Kadriu; Sarangan Ravichandran; Patrick J Morris; Peixiong Yuan; Craig J Thomas; Todd D Gould; Luigi Ferrucci; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2018-08-16       Impact factor: 4.530

7.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors:  Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2020-11-11       Impact factor: 4.356

8.  Sex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats.

Authors:  Kristin J Schoepfer; Caroline E Strong; Samantha K Saland; Katherine N Wright; Mohamed Kabbaj
Journal:  Physiol Behav       Date:  2017-10-18

9.  A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.

Authors:  Samuel T Wilkinson; Mesut Toprak; Mason S Turner; Steven P Levine; Rachel B Katz; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-07-01       Impact factor: 18.112

Review 10.  Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.

Authors:  Domenico De Berardis; Michele Fornaro; Alessandro Valchera; Marilde Cavuto; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Annastasia Fiengo; Antonio Ventriglio; Kim Yong-Ku; Giovanni Martinotti; Massimo Di Giannantonio; Carmine Tomasetti
Journal:  Int J Mol Sci       Date:  2018-09-23       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.